Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
August 6, 2015European Heart JournalOpen Access

Oral dual antiplatelet therapy: what have we learnt from recent trials?

View Full Paper
Ask AI
Bookmark
Share

Why the study?

What is the optimal timing of initiation and duration of dual antiplatelet therapy in coronary patients?

Population

Coronary patients, including stable patients undergoing percutaneous coronary intervention with drug-eluting…

Design

Review

Key result

Recent trials suggest DAPT duration should be individualized, with at least 6 months for stable PCI patients and prolonged therapy for ACS patients tolerating it well.

Authors

GMGilles MontalescotMSMarc S. Sabatine

Discussion

Loading...

Member takes

Overview

Supports individualized DAPT decisions in coronary patients; leaves open optimal pre-treatment timing by ACS subtype.

Structured PICO

What is the optimal timing of initiation and duration of dual antiplatelet therapy in coronary patients?

P
Population
Coronary patients, including stable patients undergoing percutaneous coronary intervention with drug-eluting stents and patients with acute coronary syndrome
I
Intervention
Dual antiplatelet therapy (aspirin plus a P2Y12 inhibitor)

Individualized management of DAPT duration is recommended, balancing ischemic benefits against bleeding risks based on patient clinical profiles.

Cite This Study

Montalescot et al. (2015) conducted a review in Coronary artery disease / Acute coronary syndrome. Dual antiplatelet therapy (DAPT) was evaluated. Recent trials suggest DAPT duration should be individualized, with at least 6 months for stable PCI patients and prolonged therapy for ACS patients tolerating it well.

synapsesocial.com/papers/6aa8c1caa874aacce76c7f9fhttps://doi.org/10.1093/eurheartj/ehv377
View Full Paper
Ask AI
Bookmark
Share